Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.
Adipose Tissue
/ drug effects
Adiposity
/ drug effects
Aged
Benzhydryl Compounds
/ therapeutic use
Blood Glucose
/ drug effects
Diabetes Mellitus, Type 2
/ drug therapy
Double-Blind Method
Down-Regulation
/ drug effects
Female
Germany
Glucosides
/ therapeutic use
Humans
Hypoglycemic Agents
/ therapeutic use
Insulin Resistance
Liver
/ drug effects
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ prevention & control
Placebos
Weight Loss
/ drug effects
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
29
03
2019
accepted:
21
08
2019
pubmed:
22
9
2019
medline:
28
10
2020
entrez:
22
9
2019
Statut:
ppublish
Résumé
To evaluate whether the sodium-glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). Patients with T2D ( EMPA treatment resulted in a placebo-corrected absolute change of -1.8% (95% CI -3.4, -0.2; EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.
Identifiants
pubmed: 31540903
pii: dc19-0641
doi: 10.2337/dc19-0641
doi:
Substances chimiques
Benzhydryl Compounds
0
Blood Glucose
0
Glucosides
0
Hypoglycemic Agents
0
Placebos
0
empagliflozin
HDC1R2M35U
Types de publication
Clinical Trial, Phase IV
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
298-305Informations de copyright
© 2019 by the American Diabetes Association.